Collagen Binding Provides a Sensitive Screen for Variant von Willebrand Disease
Open Access
- 1 April 2013
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (4), 684-691
- https://doi.org/10.1373/clinchem.2012.199000
Abstract
BACKGROUND von Willebrand factor (VWF) is a multimeric protein that binds platelets and collagen, facilitating hemostasis at sites of vessel injury. Measurement of VWF multimer distribution is critical for diagnosis of variant von Willebrand disease (VWD), particularly types 2A and 2B, but the typical measurement by gel electrophoresis is technically difficult and time-consuming. A comparison of VWF collagen binding (VWF:CB) and VWF multimer distribution was performed to evaluate the utility of VWF:CB as a diagnostic test. METHODS Participants were enrolled in the Zimmerman Program for the Molecular and Clinical Biology of VWD. VWF:CB was analyzed with type III collagen and multimer distribution by agarose gel electrophoresis. The study population included 146 healthy controls, 351 individuals with type 1 VWD, and 77 with type 2 VWD. Differences between individuals with multimer group results within (controls) and outside the reference intervals were assessed with Mann–Whitney tests. RESULTS The mean VWF:CB/VWF antigen ratio was 1.10 for individuals with multimer distribution within the reference intervals and 0.51 for those with multimer distribution outside the reference intervals (P < 0.001). Sensitivity of VWF:CB for multimer abnormalities was 100% for healthy controls, 99% for patients with type 1, and 100% for patients with type 2A and type 2B VWD using a VWF:CB/VWF antigen cutoff ratio of 0.6, and decreased to 99% for all patients with a ratio of 0.7. With the exception of individuals with novel or unclassified mutations, the VWF:CB was able to correctly categorize participants with variant VWD. CONCLUSIONS These findings suggest that VWF:CB may substitute for multimer distribution in initial VWD testing, although further studies are needed to validate the clinical utility of VWF:CB.Keywords
This publication has 39 references indexed in Scilit:
- Critical von Willebrand factor A1 domain residues influence type VI collagen bindingJournal of Thrombosis and Haemostasis, 2012
- VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American populationBlood, 2012
- Coating conditions matter to collagen matrix formation regarding von Willebrand factor and platelet bindingThrombosis Research, 2011
- Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactorBlood, 2010
- Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWDJournal of Thrombosis and Haemostasis, 2010
- Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factorBlood, 2009
- An Update on the von Willebrand Factor Collagen Binding Assay: 21 Years of Age and Beyond Adolescence but Not Yet a Mature AdultSeminars in Thrombosis and Hemostasis, 2007
- An External Quality Assessment Program for von Willebrand Factor Laboratory Analysis: An Overview from the European Concerted Action on Thrombosis and Disabilities FoundationSeminars in Thrombosis and Hemostasis, 2006
- Diagnosing von Willebrand Disease: A Large Reference Laboratory's PerspectiveSeminars in Thrombosis and Hemostasis, 2006
- Variant von Willebrand's DiseaseJCI Insight, 1980